| Literature DB >> 18498310 |
Christophe Sourrouille1, Estelle Marquet-Blouin, Marc-André D'Aoust, Marie-Christine Kiefer-Meyer, Martial Seveno, Sophie Pagny-Salehabadi, Muriel Bardor, Gaelle Durambur, Patrice Lerouge, Louis Vezina, Véronique Gomord.
Abstract
SUMMARY: Compared with other plant expression systems used for pharmaceutical protein production, alfalfa offers the advantage of very homogeneous N-glycosylation. Therefore, this plant was selected for further attempts at glycoengineering. Two main approaches were developed in order to humanize N-glycosylation in alfalfa. The first was a knock-down of two plant-specific N-glycan maturation enzymes, beta1,2-xylosyltransferase and alpha1,3-fucosyltransferases, using sense, antisense and RNA interference strategies. In a second approach, with the ultimate goal of rebuilding the whole human sialylation pathway, human beta1,4-galactosyltransferase was expressed in alfalfa in a native form or in fusion with a targeting domain from N-acetylglucosaminyltransferase I, a glycosyltransferase located in the early Golgi apparatus in Nicotiana tabacum. Both knock-down and knock-in strategies strongly, but not completely, inhibited the biosynthesis of alpha1,3-fucose- and beta1,2-xylose-containing glycoepitopes in transgenic alfalfa. However, recombinant human beta1,4-galactosyltransferase activity in transgenic alfalfa completely prevented the accumulation of the Lewis a glycoepitope on complex N-glycans.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18498310 DOI: 10.1111/j.1467-7652.2008.00353.x
Source DB: PubMed Journal: Plant Biotechnol J ISSN: 1467-7644 Impact factor: 9.803